RxDoctor Payments Data

Christian Hettinger, MD

Urology · Overland Park, KSNPI 1245249044

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (54.2%), education and travel and lodging — rather than concentrated in one kind of arrangement. 56 manufacturers reported payments, led by Intuitive Surgical at 43.7% of the total. Reporting peaked in 2019 at $4,475 and has fallen 66.3% since, to $1,508 in 2025.

$13,741in general payments, 2019–2025

Across 281 payments — averaging $48.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$6K
  • Mevion_medical_systems_inc$823
  • Dendreon Pharmaceuticals LLC$713
  • Johnson & Johnson$697
  • Bayer$469
  • Astellas Pharma US Inc$458
  • plus $5K from 50 others

What the payments were for

  • Speaking & faculty fees$1,2509%
  • Travel & lodging$1,74413%
  • Food & beverage$7,45054%
  • Education$3,29824%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,741 in reported general payments places this provider in the 85th percentile of 111 urology providers in Kansas.

See all urology providers in Kansas

Medicare billing

Part B allowed, 2024
$411,629
Medicare patients
1,496
Services billed
23,999

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron155$116,237
MyrbetriqMirabegron60$54,235
OrgovyxRelugolix15$39,926
Tamsulosin Hcl1,112$16,682
Silodosin182$14,582
Finasteride328$3,758
Cephalexin52$1,417
Potassium Citrate ErPotassium Citrate13$1,250
Dutasteride21$799
Alfuzosin Hcl ErAlfuzosin Hcl30$635
Oxycodone Hcl18$71
Amoxicillin20$69
Ciprofloxacin Hcl11$39

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$190$156,163170 claims
Astellas Pharma US IncMyrbetriq$458$54,23560 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 111 urology providers in Kansas.

Other urology in Overland Park

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →